Cargando…
Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
Lung cancer still represents the leading cause of cancer-related mortality. However, the recent advent of tyrosine kinase inhibitors (TKI), pioneering drugs against targetable mutations, have dramatically improved prognosis of advanced non-small cell lung cancer (NSCLC) patients. Anaplastic lymphoma...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798861/ https://www.ncbi.nlm.nih.gov/pubmed/35117063 http://dx.doi.org/10.21037/tcr.2018.10.23 |